Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12673MR)

This product GTTS-WQ12673MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12673MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3685MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ1788MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ15185MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ4042MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ2127MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ15360MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ2686MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ10905MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW